invest summari still like stock despit lower financi
guidanc remaind concern earn visibl murki
continu believ lot valu unlock
sharehold therefor multipl expans upward earn revis
drive share higher view share
posit quarter support thesi announc
intent separ rx busi tax-effici separ
sharehold sale merger enter licens agreement
pursu regulatori approv non-prescript nasonex nasal spray
receiv final approv fda store brand over-the-counter
equival imodium plan launch
announc settl litig brought leo pharma cover
net sale grew yoy organ constant currenc basi exclud
anim health busi chca achiev sale flat yoy
constant currenc basi chc america grew exclud anim health
busi chci realiz sale decreas yoy
net sale increas yoy organ constant currenc basi chci
report oper margin deliv adjust oper margin
rx realiz net sale cash flow
oper repres convers adjust net incom
repurchas share quarter board
director approv new share repurchas author
murray kessler new ceo meet investor sell
side listen tour next month concurr
develop strateg plan posit share full plan
earli spring murray note earn call base know
today would mistak straight line impli ep number
color guidanc come februari
report ep factset consensu
higher estim despit beat lower
ep guidanc factset consensu
primarili due revis expect rx addit reduc
margin expect chca expect partial off-set improv
margin expect chci updat financi model
decreas ep estim
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
gener drug price stabil goe downsid risk
entir gener industri custom consolid creat greater leverag buy
consortium extract price concess gener compani
gener consolid may make harder compet small mid-siz
gener compani need consolid stay competit market custom
increas buy power competitor get bigger stay
could make hard compet industri
competit perrigo over-the-counter product europ could neg effect
market share price could make hard meet financi
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario estim likelihood share price
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casegrow chc sale industryomega turnaround better expecteddebt paydown better expectednew launch better expectedflea tick cough cold allergi season better scenario casegrow chc sale industryomega turnaround in-lin expectationsdebt paydown in-lin expectationsnew launch in-lin expectationsflea tick cough cold allergi season in-lin scenario casegrow chc sale industryomega turnaround expectationsdebt paydown expectationsnew launch expectationsflea tick cough cold allergi season scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot driven new product sale well part chca chci gross oper oper non oper pre-tax tax net averag oper cantor fitzgerald research compani estim exhibit catalyst event calendar
datedriverupcom dm pend approv gener per multi-sympton relief launch over-the-counter hfalaunch per settlement agreement singl entityresolv excipi issu re-launch per settlement brimonidin topic gel stay expiresspr new strateg separ rx stay expiresearli stay foam stay lotion stay expir spray stay launch gener march naloxon stay expiresend april tavaborol topic solut stay expir decemb topic solut stay launch gener per settlementsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
diversifi store brand brand consum rx pharmaceut compani believ continu
market leader store brand brand consum drug forese futur
